Last reviewed · How we verify

NCT03660982

Familial Aggregation and Biomarkers in REM Sleep Behaviour Disorder.

Status unknown Last updated 6 August 2021
What this trial tests

trial in REM Sleep Behavior Disorder in 400 participants. Status unknown.

Timeline
1 October 2014
Primary endpoint
30 September 2022
30 September 2022

Quick facts

Lead sponsorChinese University of Hong Kong
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment400
Start date1 October 2014
Primary completion30 September 2022
Estimated completion30 September 2022
Sites1 location across Hong Kong

Conditions studied

Sponsor

Chinese University of Hong Kong

Who can join

40 and older, any sex, with REM Sleep Behavior Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this cohort study, the investigators aim to study the familial aggregation of REM sleep behavior disorder (RBD) and compare the differences in major biomarkers of neurodegeneration, including percentage of EMG activity during REM sleep, cognitive functions, autonomic dysfunction, and psychiatric disorders, between unaffected first degree relatives of RBD cases and non-RBD controls.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for REM Sleep Behavior Disorder

Currently open trials in the same condition.

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03660982.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing